Hydrogen-Rich Water Ameliorates Metabolic Disorder via Modifying Gut Microbiota in Impaired Fasting Glucose Patients: A Randomized Controlled Study.
Bing Liang, Le Shi, Dongyue Du, Hua Li, Ning Yi, Yue Xi, Jianjiao Cui, Ping Li, Hongbin Kang, Mami Noda, Xuejun Sun, Jiankang Liu, Shucun Qin, Jiangang Long · Antioxidants (Basel, Switzerland) · 2023
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In participants with IFG were enrolled in a randomized, H₂ slightly improved metabolic abnormalities and gut microbiota dysbiosis, providing a novel target and theoretical basis for the prevention and treatment of blood glucose regulation in patients with IFG. These findings add human evidence supporting molecular hydrogen's therapeutic potential for recovery after myocardial infarction.
What the Findings Mean
H2HUBB reviewed how hydrogen-rich water affected the outcomes measured in participants with IFG were enrolled in a randomized. H₂ slightly improved metabolic abnormalities and gut microbiota dysbiosis, providing a novel target and theoretical basis for the prevention and treatment of blood glucose regulation in patients with IFG.
What the Researchers Studied
The researchers studied participants with IFG were enrolled in a randomized. The study used a randomized, double-blind, placebo-controlled human clinical trial. The comparison condition was placebo.
What Effects Did Molecular Hydrogen Have?
Source-reported hydrogen concentration: 1.4 mg/L H₂; Source-reported hydrogen exposure: 1 L hydrogen-rich water/day; dissolved H₂ concentration was not sufficiently reported, so H2HUBB did not estimate milligrams of H₂; H2HUBB calculated daily H₂ dose: approximately 1.4 mg H₂/day, calculated from the source-reported dissolved H₂ concentration and total hydrogen-water volume consumed per day; reported treatment duration: 8 weeks. H₂ slightly improved metabolic abnormalities and gut microbiota dysbiosis, providing a novel target and theoretical basis for the prevention and treatment of blood glucose regulation in patients with IFG.
Why These Findings Matter
These findings add human evidence supporting molecular hydrogen's therapeutic potential for recovery after myocardial infarction and contribute to the growing body of molecular-hydrogen research.
How Strong Is This Evidence?
This is human clinical evidence from a randomized, double-blind, placebo-controlled human clinical trial. H2HUBB interprets the findings in the context of the study design, sample, comparator, and measured outcomes rather than using one publication as a verdict on hydrogen therapy.
Technical Study Details
H2HUBB classifies this publication as human clinical study with human clinical evidence. The research population or model was participants with IFG were enrolled in a randomized. The reported sample size was 3. The study used a randomized, double-blind, placebo-controlled human clinical trial. The hydrogen delivery method was hydrogen-rich water. The source-reported hydrogen concentration was 1.4 mg/L H₂. This is a deterministic dose translation, not a separately measured value. The reported treatment duration was 8 weeks.
Limitations and Safety
Reported limitations: This raised the uncertainty of the biological and physiological relevance of the findings.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.